deltatrials
Completed OBSERVATIONAL NCT02499263

A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice (EUREKA)

A Prospective Multicenter Study to Observe the Effectiveness on Ulcerative Colitis and Predictive Factors of Clinical Response in Korean Patients Treated With Adalimumab (EUREKA Study)

Sponsor: AbbVie

Conditions Ulcerative Colitis
Updated 18 times since 2017 Last updated: Oct 9, 2019 Started: Jun 11, 2015 Primary completion: Sep 17, 2018 Completion: Sep 17, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02499263, this observational or N/A phase trial focuses on Ulcerative Colitis and remains completed. Sponsored by AbbVie, it has been updated 18 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshot~Dec 2019 – ~Nov 2020 · 11 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Dec 2021 — Jul 2024 [monthly]

    Completed

  5. Jan 2021 — Dec 2021 [monthly]

    Completed

▶ Show 13 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed

  2. Dec 2019 — Nov 2020 [monthly]

    Completed

  3. Dec 2018 — Dec 2019 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  4. Sep 2018 — Dec 2018 [monthly]

    Active Not Recruiting

  5. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting

  6. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting

  7. Apr 2018 — May 2018 [monthly]

    Active Not Recruiting

    Phase: NA → None

  8. Mar 2018 — Apr 2018 [monthly]

    Active Not Recruiting NA

  9. Jan 2018 — Mar 2018 [monthly]

    Active Not Recruiting NA

  10. Sep 2017 — Jan 2018 [monthly]

    Active Not Recruiting NA

  11. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting NA

  12. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting NA

    Status: Recruiting → Active Not Recruiting

  13. Jan 2017 — Jun 2017 [monthly]

    Recruiting NA

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations